Lonza Group, CH0013841017

Lonza Group stock heads into the open after a 0.7% slip

Published on 09/16/2026 at 07:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 15, 2026, Lonza Group stock stood around CHF 530 on the SIX Swiss Exchange, down about 0.7%. The share remained well above its 52-week low and below its recent high, as construction of a new U.S. facility set the backdrop for today.

Fotorealistische Reinraum-Bioreaktor-Halle mit glänzenden Edelstahltanks und steriler LED-Beleuchtung
Lonza CH0013841017 zeigt Reinraum Bioreaktor Halle mit Edelstahl Tanks steriler LED Beleuchtung, Illustration mit AI erstellt.

Lonza Group stock closed near CHF 530 on the SIX Swiss Exchange on September 15, 2026, losing roughly 0.7% for the session. The move left the shares trading between their 52-week low around CHF 454 and the 52-week high near CHF 598, both reached earlier in 2026.

September 15, 2026 in numbers

Lonza Group AG (ISIN CH0013841017) ended trading on the SIX Swiss Exchange on September 15, 2026 at about CHF 530, compared with a prior close close to CHF 534, which translates into a decline of around 0.7% for the day per market data from Valiant and Finanzen.ch. In the same data overview, the 52-week low was shown at CHF 454.60 on March 23, 2026 and the 52-week high at CHF 597.80 on August 25, 2026, so the latest close remained roughly CHF 75 above the low and nearly CHF 68 below the high.

According to an article from Ad-hoc-news, Lonza said on September 14, 2026 that it had begun construction of a new pharmaceutical manufacturing facility in Bend, Oregon, aimed at strengthening Central Oregon as a hub for medicines development and adding more than 80 new jobs. The same report noted Lonza shares around CHF 530.20 late in the September 15, 2026 session, with a modest loss of about 0.75% and a market capitalization near CHF 39.9 billion, while the broader market faced pressure from higher oil prices and rising bond yields as described in a global wrap by Swissinfo.

Conference appearance and macro backdrop today

Today, Lonza remains in focus for investors following its participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, where management discussed the transition toward a more focused contract development and manufacturing model and demand trends, as summarized by TradingView. Broader European equities have lately been pressured by renewed inflation and interest-rate concerns linked to oil price gains and higher bond yields, as highlighted in a regional markets story from Morningstar, a context that may continue to shape sentiment toward Swiss blue-chip stocks such as Lonza Group today.

Disclaimer...

en | CH0013841017 | LONZA GROUP | boerse | 70108746 | bgmi